Introduction: Prostate cancer (PC) is the second most frequently diagnosed tumor in men, and bone scan (BS) is one of the diagnostic images used for staging and follow-up. Precise indications for performing a BS exist and an overuse of this diagnostic modality is suspected. It is relevant to evaluate the medical pertinence when requesting a BS to promote self-regulation, protect the health system and reduce radiation doses. Methods: This is a descriptive, retrospective study. Medical records of patients with PC diagnosis were reviewed. We included patients evaluated by a urologic oncologist at the outpatient scenario, at San Ignacio Hospital, Bogotá, Colombia, in the second trimester of 2019. Epidemiological and staging data were recorded for each patient, as well as the number of BS requested, the type of BS performed, the PSA at the time of performance and the impact of the result on medical decisions. Clinical indications for requesting a BS were classified, according to RADAR III guidelines. An analysis was performed using Excel (measures of central tendency and frequency). Results: A total of 234 patients were evaluated (mean age: 74.47 years; mean follow-up time: 32.3 months). At least one BS was requested in 55% of patients (mean 1.54), with a total of 199 BS performed. The most frequent indication for a BS was PSA progression in patients with androgen deprivation therapy (ADT), in hormone-sensitive prostate cancer (31%). 18% of the requested BS could have been omitted (inappropriate indication). The mean PSA at performance for BS that showed bone metastasis (33%) was 151.27ng/ml and 19.75ng/ml for those negative (67%). Medical behavior was not impacted by the result of any of the BS that didn´t have an appropriate indication according to the established guidelines, but it was affected by 85% of those correctly requested. Discussion and Conclusions: BS is a conventional image that it widely performed for the staging and follow-up of PC. There are precise indications according to the NCCN and RADAR III guidelines for performing one in a PC patient. It was observed that with some frequency it is requested unnecessarily, without having any impact on the clinical decisions for the patient. The relevance of medical self-regulation and knowledge of scientific evidence are highlighted to prevent unnecessary exposure to radiation, optimize the impact of the results of these tests on clinical behavior and protect the health system.
| Published in | International Journal of Clinical Urology (Volume 5, Issue 2) |
| DOI | 10.11648/j.ijcu.20210502.12 |
| Page(s) | 64-69 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Bone Scan, Medical Pertinence, Prostate Cancer
| [1] | Colombian Ministry of Health Clinical Practice Guidelines for the early detection follow-up and rehabilitation of prostate cancer. Colombian Ministry of Health. Colombia. 2013. |
| [2] | “Global Cancer Observatory,” World Health Organization. International Agency For Research on Cancer, 2018. |
| [3] | K. J. L. Bell, C. Del Mar, G. Wright, J. Dickinson, and P. Glasziou, “Prevalence of incidental prostate cancer: A systematic review of autopsy studies.,” Int. J. cancer, vol. 137, no. 7, pp. 1749–57, Oct. 2015. |
| [4] | L. Acuña, L. A. Soler, and F. Valderrama, “Cáncer de Próstata. Cuenta de Alto Costo 2018.,” Bogota, Colombia, 2018. |
| [5] | A. J. Armstrong et al., “NCCN Guidelines Panel Disclosures NCCN Guidelines Version 2.2019 Prostate Cancer,” 2019. |
| [6] | E. D. Crawford et al., “A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III),” J. Urol., vol. 201, no. 4, pp. 682–692, 2019. |
| [7] | G. Shen, H. Deng, S. Hu, and Z. Jia, “Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis,” Skeletal Radiol., vol. 43, no. 11, pp. 1503–1513, Nov. 2014. |
| [8] | D. Ilic et al., “Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis,” BMJ, vol. 362, 2018. |
| [9] | C. Love, A. S. Din, M. B. Tomas, T. P. Kalapparambath, and C. J. Palestro, “Radionuclide Bone Imaging: An Illustrative Review,” Radio Graphics, vol. 23, no. 2, pp. 341–358, Mar. 2003. |
| [10] | Pr. Manohar, T. Rather, and S. Khan, “Determination of the optimal cut-off value of serum prostate-specific antigen in the prediction of skeletal metastases on technetium-99m whole-body bone scan by receiver operating characteristic curve analysis,” World J. Nucl. Med., vol. 19, no. 3, p. 255, 2020. |
| [11] | C. H. Suh, A. B. Shinagare, A. M. Westenfield, N. H. Ramaiya, A. D. Van den Abbeele, and K. W. Kim, “Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis,” Clin. Radiol., vol. 73, no. 2, pp. 158–167, Feb. 2018. |
| [12] | S. Kosuda et al., “Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?,” J. Nucl. Med., vol. 37, no. 6, pp. 975–8, Jun. 1996. |
| [13] | N. Ghanem et al., “Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone,” Eur. J. Radiol., vol. 55, no. 1, pp. 41–55, Jul. 2005. |
| [14] | Colombian Congress, Estatutary Law, 1751 of 2015. |
| [15] | J. Calderón, “Autonomía médica y ley estatutaria de salud,” Actas Medicas Colombianas, pp. 51–53, Jan-2015. |
| [16] | F. A. Mettler, W. Huda, T. T. Yoshizumi, and M. Mahesh, “Effective doses in radiology and diagnostic nuclear medicine: A catalog,” Radiology, vol. 248, no. 1. pp. 254–263, Jul-2008. |
APA Style
Maria Camila Moreno Bencardino, Andrea Camila Araujo, Valeria Restrepo, Juan Guillermo Catano, Andres Felipe Gutierrez, et al. (2021). Characterizing the Medical Pertinence for the Indication of a Bone Scan by Urologists, in Patients with Prostate Cancer. International Journal of Clinical Urology, 5(2), 64-69. https://doi.org/10.11648/j.ijcu.20210502.12
ACS Style
Maria Camila Moreno Bencardino; Andrea Camila Araujo; Valeria Restrepo; Juan Guillermo Catano; Andres Felipe Gutierrez, et al. Characterizing the Medical Pertinence for the Indication of a Bone Scan by Urologists, in Patients with Prostate Cancer. Int. J. Clin. Urol. 2021, 5(2), 64-69. doi: 10.11648/j.ijcu.20210502.12
AMA Style
Maria Camila Moreno Bencardino, Andrea Camila Araujo, Valeria Restrepo, Juan Guillermo Catano, Andres Felipe Gutierrez, et al. Characterizing the Medical Pertinence for the Indication of a Bone Scan by Urologists, in Patients with Prostate Cancer. Int J Clin Urol. 2021;5(2):64-69. doi: 10.11648/j.ijcu.20210502.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcu.20210502.12,
author = {Maria Camila Moreno Bencardino and Andrea Camila Araujo and Valeria Restrepo and Juan Guillermo Catano and Andres Felipe Gutierrez and Jaime Andres Cajigas},
title = {Characterizing the Medical Pertinence for the Indication of a Bone Scan by Urologists, in Patients with Prostate Cancer},
journal = {International Journal of Clinical Urology},
volume = {5},
number = {2},
pages = {64-69},
doi = {10.11648/j.ijcu.20210502.12},
url = {https://doi.org/10.11648/j.ijcu.20210502.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20210502.12},
abstract = {Introduction: Prostate cancer (PC) is the second most frequently diagnosed tumor in men, and bone scan (BS) is one of the diagnostic images used for staging and follow-up. Precise indications for performing a BS exist and an overuse of this diagnostic modality is suspected. It is relevant to evaluate the medical pertinence when requesting a BS to promote self-regulation, protect the health system and reduce radiation doses. Methods: This is a descriptive, retrospective study. Medical records of patients with PC diagnosis were reviewed. We included patients evaluated by a urologic oncologist at the outpatient scenario, at San Ignacio Hospital, Bogotá, Colombia, in the second trimester of 2019. Epidemiological and staging data were recorded for each patient, as well as the number of BS requested, the type of BS performed, the PSA at the time of performance and the impact of the result on medical decisions. Clinical indications for requesting a BS were classified, according to RADAR III guidelines. An analysis was performed using Excel (measures of central tendency and frequency). Results: A total of 234 patients were evaluated (mean age: 74.47 years; mean follow-up time: 32.3 months). At least one BS was requested in 55% of patients (mean 1.54), with a total of 199 BS performed. The most frequent indication for a BS was PSA progression in patients with androgen deprivation therapy (ADT), in hormone-sensitive prostate cancer (31%). 18% of the requested BS could have been omitted (inappropriate indication). The mean PSA at performance for BS that showed bone metastasis (33%) was 151.27ng/ml and 19.75ng/ml for those negative (67%). Medical behavior was not impacted by the result of any of the BS that didn´t have an appropriate indication according to the established guidelines, but it was affected by 85% of those correctly requested. Discussion and Conclusions: BS is a conventional image that it widely performed for the staging and follow-up of PC. There are precise indications according to the NCCN and RADAR III guidelines for performing one in a PC patient. It was observed that with some frequency it is requested unnecessarily, without having any impact on the clinical decisions for the patient. The relevance of medical self-regulation and knowledge of scientific evidence are highlighted to prevent unnecessary exposure to radiation, optimize the impact of the results of these tests on clinical behavior and protect the health system.},
year = {2021}
}
TY - JOUR T1 - Characterizing the Medical Pertinence for the Indication of a Bone Scan by Urologists, in Patients with Prostate Cancer AU - Maria Camila Moreno Bencardino AU - Andrea Camila Araujo AU - Valeria Restrepo AU - Juan Guillermo Catano AU - Andres Felipe Gutierrez AU - Jaime Andres Cajigas Y1 - 2021/08/11 PY - 2021 N1 - https://doi.org/10.11648/j.ijcu.20210502.12 DO - 10.11648/j.ijcu.20210502.12 T2 - International Journal of Clinical Urology JF - International Journal of Clinical Urology JO - International Journal of Clinical Urology SP - 64 EP - 69 PB - Science Publishing Group SN - 2640-1355 UR - https://doi.org/10.11648/j.ijcu.20210502.12 AB - Introduction: Prostate cancer (PC) is the second most frequently diagnosed tumor in men, and bone scan (BS) is one of the diagnostic images used for staging and follow-up. Precise indications for performing a BS exist and an overuse of this diagnostic modality is suspected. It is relevant to evaluate the medical pertinence when requesting a BS to promote self-regulation, protect the health system and reduce radiation doses. Methods: This is a descriptive, retrospective study. Medical records of patients with PC diagnosis were reviewed. We included patients evaluated by a urologic oncologist at the outpatient scenario, at San Ignacio Hospital, Bogotá, Colombia, in the second trimester of 2019. Epidemiological and staging data were recorded for each patient, as well as the number of BS requested, the type of BS performed, the PSA at the time of performance and the impact of the result on medical decisions. Clinical indications for requesting a BS were classified, according to RADAR III guidelines. An analysis was performed using Excel (measures of central tendency and frequency). Results: A total of 234 patients were evaluated (mean age: 74.47 years; mean follow-up time: 32.3 months). At least one BS was requested in 55% of patients (mean 1.54), with a total of 199 BS performed. The most frequent indication for a BS was PSA progression in patients with androgen deprivation therapy (ADT), in hormone-sensitive prostate cancer (31%). 18% of the requested BS could have been omitted (inappropriate indication). The mean PSA at performance for BS that showed bone metastasis (33%) was 151.27ng/ml and 19.75ng/ml for those negative (67%). Medical behavior was not impacted by the result of any of the BS that didn´t have an appropriate indication according to the established guidelines, but it was affected by 85% of those correctly requested. Discussion and Conclusions: BS is a conventional image that it widely performed for the staging and follow-up of PC. There are precise indications according to the NCCN and RADAR III guidelines for performing one in a PC patient. It was observed that with some frequency it is requested unnecessarily, without having any impact on the clinical decisions for the patient. The relevance of medical self-regulation and knowledge of scientific evidence are highlighted to prevent unnecessary exposure to radiation, optimize the impact of the results of these tests on clinical behavior and protect the health system. VL - 5 IS - 2 ER -
Information
Email: